Our client sought to assess a broad range of indications in which gene therapy is being developed and create a comprehensive map of the landscape to facilitate comparison of indications. This would then be used to assess the relative attractiveness of individual indications and broader therapy areas.
CRA approach
- Generated a full list of clinical and some preclinical indications (~80) of interest based on ongoing programs and clinical trials
- Assessed indications against five key criteria: epidemiology, unmet need, target confidence, competition, and feasibility
- Provided a one-slide, high-level summary of each indication detailing rationale for value assigned to each key criteria
- Created an unbiased map of opportunities and conducted analyses within and across disease areas to identify opportunities for efficiencies
Client impact
- Identified opportunity archetypes that may justify diversifying clients’ existing therapy area focus and creation of a new vertical
- Created a guide for future business development (BD) activities:
- Identified diseases where the team should conduct the next deep-dive assessments
- Created a list of top priority indications to communicate with the BD community such that the client can become a partner of choice
- Aided in understanding the criteria for assessing future opportunities